WO2020098329A1 - 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 - Google Patents
牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 Download PDFInfo
- Publication number
- WO2020098329A1 WO2020098329A1 PCT/CN2019/102475 CN2019102475W WO2020098329A1 WO 2020098329 A1 WO2020098329 A1 WO 2020098329A1 CN 2019102475 W CN2019102475 W CN 2019102475W WO 2020098329 A1 WO2020098329 A1 WO 2020098329A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- antrodia camphorata
- cancer
- antrodia
- composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the invention relates to the technical field of application of edible and medicinal bacteria, in particular to a preparation method of antrodia cinnamomea extract and antrodia cinnamomea composition for treating cancer and alleviating side effects of chemotherapy, and a pharmaceutical composition.
- Antrodia cinnamomea belongs to the non-folded fungus, porous fungus material, thin-hole fungus, Antrodia cinnamomea, is a perennial fungus, and is a unique mushroom species in Taiwan.
- the current research results show that Antrodia cinnamomea has anti-tumor and enhanced immunity , Anti-virus, anti-inflammatory, anti-oxidation effect and liver protection effect and other functions.
- anti-tumor related research and patents are concentrated on the direct use of basswood cultivated Antrodia camphorata fruiting bodies or mycelium powder or extracts or single compounds of different solvents on cancer cells.
- Antrodia cinnamomea Due to the scarcity of wild Antrodia cinnamomea and the problems of growing environment pollution, artificial cultivation methods have been used to cultivate Antrodia cinnamomea in recent years.
- the main production methods of Antrodia cinnamomea include liquid culture method, solid culture method and basswood culture method.
- the type and composition of Antrodia camphorata will vary greatly depending on the cultivation method. According to literature reports, the cultivation of Antrodia cinnamomea by liquid fermentation and solid fermentation is the mycelium of Antrodia camphorata, and the cultivation by basswood cultivation method is Antrodia cinnamomea fruiting body.
- the composition of Antrodia cinnamomea mycelia is mainly composed of polysaccharides, while the composition of Antrodia cinnamomea fruiting bodies is mainly triterpenoids. Because the Antrodia cinnamomea is not easy to obtain, the Antrodia cinnamomea fruiting bodies cultivated with basswood are very expensive.
- Cancer is a disease with a high prevalence and fatality rate all over the world.
- Cancer treatment methods include surgery, chemotherapy, radiation therapy, target therapy, and a combination of these treatment methods.
- chemotherapy can successfully kill cancer cells, it will not selectively kill normal cells, and it will usually have serious side effects on patients.
- the low number of white blood cells caused by chemotherapy drugs is one of the common side effects. Cancer patients The number of white blood cells is often too low during chemotherapy to affect the treatment. Therefore, looking for extracts of Chinese herbal medicines with anti-cancer activity from traditional Chinese herbal medicines to replace western medicines or combine with western medicines to treat cancer is a new direction worthy of research.
- the present invention provides a preparation method of Antrodia cinnamomea extract, which includes the following steps: using an ethanol solution to extract the cultured Antrodia cinnamomea fruit body powder, and filtering the liquid
- the crude extract is obtained after concentration under reduced pressure; the crude extract is adsorbed with a macroporous resin and placed in a rectangular container, followed by elution with a mixed solution, and the eluate is concentrated and dried under reduced pressure to obtain an Antrodia camphorata extract
- the first sub-extract elute with ethanol solution, concentrate and dry the eluent under reduced pressure to obtain the second sub-extract of Antrodia camphorata extract, and then elute with ethyl acetate solution, reduce the eluent It was concentrated by pressure and dried to obtain the third fraction of Antrodia camphorata extract.
- the mixed solution is composed of secondary water and ethanol solution; wherein the volume ratio of the secondary water and ethanol solution is (40-60): (40-60).
- the volume fraction of the ethanol solution is 95%.
- the invention provides a preparation method of Antrodia camphorata composition, which comprises the following steps: extracting Mycelium powder of Antrodia camphorata using secondary water, and the filtrate is concentrated under reduced pressure to obtain a concentrated solution; the concentrated solution is added to an ethanol solution and filtered Taking the precipitate; drying the precipitate to obtain the Antrodia camphorata mycelium extract; combining the Antrodia camphorata mycelium extract with the second sub-extract of the Antrodia camphorata extract prepared as described above to obtain the Antrodia camphorata composition .
- the weight ratio of the Antrodia camphorata mycelium extract and the second sub-extract of Antrodia camphorata extract is (35-65): (35-65).
- the volume ratio of the concentrated solution to the ethanol solution is 1: 3; the volume fraction of the ethanol solution is 60% to 80%.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective dose of the crude extract prepared as described above and optionally a pharmaceutically acceptable carrier for the preparation of prevention or treatment of colorectal cancer and liver cancer And skin cancer medicines; the medicines have a toxic effect on colorectal cancer, liver cancer and skin cancer cells.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective dose of the second or third sub-extract of Antrodia camphorata extract prepared as described above and optionally a pharmaceutically acceptable carrier
- the medicine is used for preparing medicines for preventing or treating colorectal cancer, liver cancer, stomach cancer, lung cancer, breast cancer and skin cancer; the medicines have a toxic effect on colorectal cancer, liver cancer, stomach cancer, lung cancer, breast cancer and skin cancer cells.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective dose of Antrodia camphorata composition prepared as described above and optionally a pharmaceutically acceptable carrier for the preparation of chemotherapeutic drugs cisplatin and Medicines containing platinum series drugs causing side effects; the medicines can improve the phenomenon of low white blood cells and bone marrow suppression caused by the chemotherapy drugs cisplatin series drugs.
- the extract of Antrodia camphorata extract or Antrodia camphorata composition prepared by the method provided by the present invention can be used to treat cancer and reduce the side effects of chemotherapy, including the treatment of liver cancer, lung cancer, colorectal cancer, gastric cancer, breast cancer and skin cancer, etc.
- the low number of white blood cells caused by chemotherapy drugs and bone marrow suppression have a significant effect.
- 1 is a flow chart of the preparation method of Antrodia camphorata extract provided by an embodiment of the present invention
- FIG. 2 is a flowchart of a preparation method of Antrodia cinnamomea mycelium extract provided by an embodiment of the present invention
- Antrodia cinnamomea extract extract F2 on human intestinal cancer cell HCT116 animal model tumor suppression efficacy test;
- FIG. 4 is the effect of the extract of Antrodia camphorata extract (F2) on the body weight of human intestinal cancer cell HCT116 in an embodiment of the present invention
- FIG. 5 is the effect of the Antrodia camphorata composition on the number of white blood cells caused by the chemotherapeutic drug cisplatin in normal mice immunized with C57BL / 6;
- FIG. 6 is the effect of Antrodia camphorata composition on chemotherapeutic drug cisplatin in C57BL / 6 immunized normal mouse leukocyte precursor cells;
- FIG. 7 is the effect of Antrodia camphorata composition on erythrocyte precursor cells immunized with chemotherapeutic drug cisplatin in C57BL / 6 normal mice.
- the Antrodia camphorata extract provided by the embodiment of the present invention is an extract of antrodia camphorata fruit body through ethanol solution, adsorbed by macroporous resin and placed in a rectangular container for partial purification to obtain a fractional extract, which
- the preparation method includes the following steps:
- Step S101 taking 1 kg of Antrodia cinnamomea fruit body powder, soaking and stirring for 72 hours with an ethanol solution with a volume fraction of 10 times the volume fraction of 95%, and filtering;
- Step S102 the filter residue obtained after the extraction in step S101 is immersed and stirred in an ethanol solution with a volume fraction of 10 times the volume of 95% for 72 hours, and then filtered;
- Step S103 the filtrate obtained in step S101 and the filtrate obtained in step S102 are mixed, and concentrated to 5% of the original volume using a reduced-pressure rotary concentrator to obtain a crude extract (Crude);
- Step S104 After diluting the crude extract obtained in step S103 10 times with the mixed solution, pour into the macroporous resin containing about 5 times the weight of the crude extract (for example, HP20) in a rectangular container and stir well to allow the macroporous resin to absorb the crude extract (adsorption time is 10 to 12 hours); pour out the liquid in the rectangular container and then about 3 to 6 times the 1 kg dish culture
- the mixed solution of Antrodia cinnamomea fruit body powder volume is added to the rectangular container, and after soaking for 1 to 5 hours, the solution in the rectangular container is poured out again; the liquid poured out of the rectangular container is collected twice and concentrated and dried using a reduced-pressure rotary thickener Weigh the weight to obtain the F1 extract of Antrodia camphorata extract;
- the mixed solution is composed of secondary water and an ethanol solution with a volume fraction of 95%, wherein the volume ratio of the secondary water and the ethanol solution with a volume fraction of 95% is (40-60): (40-60);
- Step S105 The macroporous resin in the rectangular container is re-used with an ethanol solution with a volume fraction of 95% of the volume of the powder of Antrodia cinnamomea fruit body powder of about 3 to 6 times the volume of 1 kg of Petri cinnamomea, and soaked for 1 to 5 hours. After the liquid, and using a reduced-pressure rotary concentrator to concentrate and dry, weigh the weight to obtain the extract F2 of Antrodia camphorata extract;
- Step S106 the macroporous resin in the rectangular container is further immersed in an ethyl acetate solution of about 3 to 6 times the volume of the powder of Antrodia cinnamomea fruit body of about 1 kg, and soaked for 1 to 5 hours. After collecting the liquid twice, After concentrating and drying using a reduced-pressure rotary concentrator, the weight is weighed to obtain a fraction F3 of Antrodia camphorata extract.
- the Antrodia cinnamomea mycelium extract uses secondary water to extract the Antrodia cinnamomea mycelium powder, the filtered concentrated solution is added to an ethanol solution, and the filtered precipitate is dried.
- the preparation method includes the following steps:
- Step S201 take 1 kg of Antrodia camphorata mycelium powder, boil with 10 times the volume of secondary water for 8 hours, and filter;
- Step S202 the filter residue obtained after the extraction in step S201 is boiled with 10 times the volume of secondary water for 4 hours, and then filtered;
- Step S203 the filtrate obtained in step S201 and the filtrate obtained in step S202 are mixed, and concentrated to 5% of the original volume using a reduced-pressure rotary concentrator;
- Step S204 add the concentrated solution obtained in step S203 to three times volume of ethanol solution with a volume fraction of 60% to 80%, take the precipitate after filtration, and dry the precipitate to obtain the Antrodia camphorata mycelium extract.
- the Antrodia camphorata mycelium extract and the extract of Antrodia camphorata extract F2 are combined according to the volume ratio (35-65): (35-65) to obtain the Antrodia camphorata composition provided by the embodiment of the present invention.
- the mixed solution consists of secondary water and an ethanol solution with a volume fraction of 95%, secondary water (The volume ratio of the ethanol solution with a volume fraction of 95% is 40:60)
- Add to the rectangular container soak for 1 to 5 hours, then pour out the solution in the rectangular container, collect the secondary filtrate, concentrate and dry, weigh the weight, An extract Fl of Antrodia camphorata extract was obtained.
- the macroporous resin in a rectangular container is re-used with an ethanol solution with a volume fraction of 95% of the volume of the powder of Antrodia cinnamomea fruit body powder of about 1 to 3 times the volume of 1 kg of Petri cinnamomea, soaked for 1 to 5 hours. After concentration and drying, the scale was weighed to obtain a fraction F2 of Antrodia camphorata extract.
- the macroporous resin in the rectangular container is then immersed in an ethyl acetate solution of about 3 to 6 times the volume of the powder of Antrodia cinnamomea fruit body of 1 kg dish for 1 to 5 hours. After collecting this liquid twice, concentrate and dry it. By weight, fraction F3 of Antrodia camphorata extract was obtained.
- the volume ratio of the secondary water in the mixed solution to the ethanol solution with a volume fraction of 95% can also be 45:55, 50:50, 55:45, or 60:40.
- this embodiment will not repeat them separately.
- volume fraction of the concentrated solution added with 3 volumes of ethanol solution may also be 60%, 65%, 75%, or 80%.
- this embodiment will not repeat them separately.
- the Antrodia cinnamomea mycelium extract obtained in Example 2 and the Antrodia cinnamomea extract obtained in Example 1 were combined in a volume ratio of 35:65 to obtain an Antrodia camphorata composition (AC).
- the volume ratio of the extract of Antrodia camphorata mycelia and the extract F2 of Antrodia camphorata extract can also be 40:60, 45:55, 50:50, 55: 45, 60:40 or 65:35 etc.
- the Antrodia cinnamomea mycelium extract and the Antrodia cinnamomea extract F2 in different volume ratios this embodiment will not repeat them separately.
- the extract of Antrodia camphorata extract or the Antrodia camphorata composition prepared by the method provided in the embodiments of the present invention can treat cancer and reduce the side effects of chemotherapy, including the treatment of liver cancer, lung cancer, colorectal cancer, gastric cancer, breast cancer and skin cancer, etc. It has a significant effect in improving the low white blood cell count and bone marrow suppression caused by chemotherapy drugs. The following will be explained by some test results.
- HCT116 human colorectal cancer cells Huh7 human liver cancer cells, MKN45 human gastric cancer cells, A549 human lung cancer cells, MDA-MB-231 human breast cancer cells and A375 human skin cancer cells
- HCT116, Huh7, A549, MDA-MB-231 and A375 DMEM culture medium containing 10% FBS was used for cells
- RPMI culture medium containing 10% FBS was used for MKN45 cells, and cultured in a humidified incubator containing 5% CO 2 at 37 ° C.
- the culture plate can be filled up in about three to seven days, remove the culture medium at the subculture, wash the cells with PBS, add trypsin-EDTA to detach the cells, and use new culture medium After the neutralization, the cell count was performed, and the appropriate cell number was planted in the culture plate according to the experiment, and 1.2 ⁇ 10 6 cells were left to be planted in the new T75flask to continue the cultivation.
- test substances including Antrodia camphorata extracts were labeled as Crude, F1, F2, and F3 with 100% DMSO, and the concentration was set to 50 mg / mL.
- DMEM or RPMI culture solution was used to dilute the test drug to the following eight concentrations: 2000, 1500, 1000, 500, 250, 50, 25 and 12.5 ⁇ g / mL, the above concentration was ten times the final concentration.
- Antrodia cinnamomea extract extract has a strong cytotoxic effect on the six cancer cells tested, especially A375 (skin cancer), Huh7 (liver cancer) and MKN-45 (stomach cancer) .
- Antrodia cinnamomea extract extract (F3) is not toxic to MDA-MB231 (breast cancer) in the 6 types of cancer cells tested, and has a strong toxic and bactericidal effect to Huh7 (liver cancer). With weak poisoning effect.
- mice used in this study were BALB / cnu / nu nude mice, purchased from the Taiwan Experimental Animal Center, six weeks old. Control feeding temperature to 25 ⁇ 2 °C, light time from 08:00 to 20:00, provide sufficient feed and drinking water every day, and change litter twice a week.
- the human intestinal cancer cell line (HCT116) was suspended in 80LPBS at a volume of 3 ⁇ 10 6 and implanted into the subcutaneous site on the right side of the back of nude mice by injection to induce tumor formation until the tumor size reached 100-200 mm 3 . Start taking medicine.
- Fraction F2 was administered by tube feeding on days 1 to 15.
- the animal groups were the control group, 100, 200 and 400 mg / kg F2, 6 mice in each group and 24 mice in 4 groups.
- mice were sacrificed by CO 2 , the tumor site was weighed after being removed by surgery, and the tumor type and weight changes after drug administration were compared. If the experimental animal has died before the sacrifice day, the time of death is recorded as a comparison basis for prolonging the life span after administration of the drug.
- the results in Figure 3 show that the extract of Antrodia camphorata extract (F2) has a dose-dependent effect on tumor inhibition when administered orally to immunodeficient mice implanted with human intestinal cancer cell HCT116 at a dose of 400 mg / kg There are obvious statistical differences between the groups. This result indicates that 400 mg / kg is a therapeutically effective dose for immunodeficient mice implanted with human intestinal cancer cell HCT116.
- the results in Figure 4 show that the three doses of Antrodia camphorata extract (F2) do not cause weight loss in immunodeficient mice implanted with human intestinal cancer cell HCT116. This result indicates that the Antrodia camphorata extract (F2) ) Does not cause side effects of weight loss when suppressing tumors.
- the animal used in this study was C57BL / 6 mice, purchased from the Taiwan Experimental Animal Center, six weeks old. Feeding control temperature is 25 ⁇ 2 °C, light time is 08: 00-20: 00, sufficient feed and drinking water are provided daily, and litter is changed twice a week.
- Cisplatin (cis, 20 mg / kg) was administered on the first day, and intraperitoneal injection was used.
- the Antrodia camphorata composition 400 mg / kg was administered by tube feeding on days 1 to 5, and the tube feeding time on the first day was 4 hours after administration of chemotherapy drugs.
- the animal groups were the control group, Cis and Antrodia camphorata composition (AC), 6 mice in each group, and 18 mice in 3 groups.
- the experimental animals were sacrificed with CO 2.
- the thigh bones of the mice were surgically removed, the bones were cut open, the bone marrow cells were punched out, and after centrifugation and washing, the cells were added to MethoCult M3334 medium or MethoCult M3234 medium and allowed to stand at 37 °C Cultivate in a humidified incubator containing 5% CO 2 , the former is observed under a microscope after 48 hours of cultivation and counts the number of colonies of CFU-E (Colony-forming unit-erythroid), the latter is observed under a microscope after 7 days of cultivation and calculates CFU-GM (Colony-forming unit-granulocyte, macrophage) colony number.
- CFU-E and CFU-GM colony numbers were counted using full-field observation.
- the whole blood was collected by cheek blood collection, and the complete blood count (CBC) was performed with anticoagulated whole blood to determine the number of peripheral blood leukocytes.
- CBC complete blood count
- the results in Figure 5 show that the chemotherapeutic drug cisplatin can reduce the number of white blood cells in immunologically normal mice.
- the Antrodia camphorata composition When the Antrodia camphorata composition is combined with the chemotherapeutic drug cisplatin, the Antrodia camphorata composition can effectively improve the decrease in the number of white blood cells caused by the chemotherapeutic drug cisplatin, making it recover comparable to the control group .
- the results in Figure 6 show that the chemotherapeutic drug cisplatin can inhibit the number of CFU-GM of bone marrow leukocyte precursor cells in immunologically normal mice.
- the Antrodia camphorata composition When the Antrodia camphorata composition is combined with the chemotherapeutic drug cisplatin, the Antrodia camphorata composition can effectively improve the myelosuppression caused by the chemotherapeutic drug cisplatin and make CFU- The number of GM has increased significantly.
- the results in Figure 7 show that the chemotherapeutic drug cisplatin can suppress the number of CFU-E of bone marrow erythrocyte precursor cells in immunologically normal mice.
- the Antrodia camphorata composition When the Antrodia camphorata composition is combined with the chemotherapeutic drug cisplatin, the Antrodia camphorata composition can effectively improve the bone marrow suppression caused by the chemotherapeutic drug cisplatin, making CFU- The number of E has increased significantly.
- the embodiments of the present invention provide a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective dose of crude extract (Crude) prepared as described above and optionally a pharmaceutically acceptable carrier for the preparation of prophylaxis Or medicines for treating colorectal cancer, liver cancer and skin cancer.
- the medicinal product has a poisonous effect on colorectal cancer, liver cancer and skin cancer cells.
- the embodiments of the present invention provide a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective dose of sub-extract F2 or sub-extract F3 of Antrodia camphorata extract prepared as described above and optionally pharmaceutically acceptable
- the carrier is used for preparing medicines for preventing or treating colorectal cancer, liver cancer, stomach cancer, lung cancer, breast cancer and skin cancer.
- the medicinal product has a toxic effect on colorectal cancer, liver cancer, stomach cancer, lung cancer, breast cancer and skin cancer cells.
- the embodiments of the present invention also provide a pharmaceutical composition, which comprises a therapeutically effective dose of Antrodia camphorata composition prepared as described above and optionally pharmaceutically acceptable carrier for the preparation of chemotherapeutic drugs Cisplatin and platinum-containing drugs cause side effects.
- the drug can improve the phenomenon of low white blood cell count and bone marrow suppression caused by the cisplatin series of chemotherapy drugs.
- cancer refers to a disease in which the growth of malignant tissue cells is out of control. This cell growth may cause metastasis and invade adjacent tissues.
- treatment means alleviating or improving the symptoms of a sick individual.
- subject as used in the present invention means an animal, especially a mammal.
- therapeutically effective dose refers to the amount of active ingredient used alone or in combination with other therapies / drugs to treat cancer to show therapeutic efficacy.
- carrier or “pharmaceutically acceptable carrier” refers to a diluent, excipient, acceptor, or the like that is well known to those skilled in the art for preparing pharmaceutical compositions.
- compositions and preparation methods in the embodiments of the present invention are representative of preferred embodiments, which are exemplary and not limited to the field of the present invention. Those skilled in the art will think of modifications and other uses. These modifications are included in the spirit of the present invention and are defined within the protection scope of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (9)
- 一种牛樟芝萃取物的制备方法,其特征在于,包括如下步骤:使用乙醇溶液萃取皿培式牛樟芝子实体粉末,过滤液减压浓缩后得到粗萃取物;将所述粗萃取物用大孔树脂吸附后置于长方形容器中,依次先用混合溶液洗脱,将洗脱液减压浓缩、干燥,得到牛樟芝萃取物的第一分萃物后,再用乙醇溶液洗脱,将洗脱液减压浓缩、干燥,得到牛樟芝萃取物的第二分萃物后,再用乙酸乙酯溶液洗脱,将洗脱液减压浓缩、干燥,得到牛樟芝萃取物的第三分萃物。
- 如权利要求1所述的牛樟芝萃取物的制备方法,其特征在于,所述混合溶液由二次水和乙醇溶液组成;其中所述二次水和乙醇溶液的体积比为(40~60):(40~60)。
- 如权利要求1或2所述的牛樟芝萃取物的制备方法,其特征在于,所述乙醇溶液的体积分数为95%。
- 一种牛樟芝组合物的制备方法,其特征在于,包括如下步骤:使用二次水萃取牛樟芝菌丝体粉末,过滤液经减压浓缩后得到浓缩液;将所述浓缩液加入乙醇溶液,过滤后取沉淀物;烘干所述沉淀物,得到牛樟芝菌丝体萃取物;将所述牛樟芝菌丝体萃取物与如权利要求1所述方法制得的牛樟芝萃取物的第二分萃物组合,得到牛樟芝组合物。
- 如权利要求4所述的牛樟芝组合物,其特征在于,所述牛樟芝菌丝体萃取物和所述牛樟芝萃取物的第二分萃物的重量比为(35~65):(35~65)。
- 如权利要求4所述的牛樟芝组合物,其特征在于,所述浓缩液与乙醇溶液的体积比为1:3;所述乙醇溶液的体积分数为60%~80%。
- 一种医药组合物,其特征在于,所述组合物包括治疗有效剂量的如权利 要求1所述方法制得的粗萃取物及视情况医药学上可接受的载剂,用于制备预防或治疗大肠癌、肝癌及皮肤癌的医药品;所述医药品对大肠癌、肝癌及皮肤癌细胞具有毒杀效果。
- 一种医药组合物,其特征在于,所述组合物包括治疗有效剂量的如权利要求1所述方法制得的牛樟芝萃取物的第二分萃物或第三分萃物及视情况医药学上可接受的载剂,用于制备预防或治疗大肠癌、肝癌、胃癌、肺癌、乳癌及皮肤癌的医药品;所述医药品对大肠癌、肝癌、胃癌、肺癌、乳癌及皮肤癌细胞具有毒杀效果。
- 一种医药组合物,其特征在于,所述组合物包括治疗有效剂量的如权利要求4所述方法制得的牛樟芝组合物及视情况医药学上可接受的载剂,用于制备改善化疗药物顺铂及含铂系列药物造成副作用的药品;所述药品可改善化疗药物顺铂系列药物造成的白血球数目低下和骨髓抑制现象。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11202104971PA SG11202104971PA (en) | 2018-11-14 | 2019-08-26 | Antrodia cinnamomea extract, method for preparing antrodia cinnamomea composition, and pharmaceutical composition |
JP2021526451A JP2022513042A (ja) | 2018-11-14 | 2019-08-26 | ベニクスノキタケ抽出物、ベニクスノキタケ組成物の製造方法及び医薬組成物 |
GB2107582.5A GB2593380A (en) | 2018-11-14 | 2019-08-26 | Antrodia cinnamomea extract, method for preparing antrodia cinnamomea composition, and pharmaceutical composition |
US17/292,610 US20220000952A1 (en) | 2018-11-14 | 2019-08-26 | Method preparing antrodia cinnamomea extract and antrodia cinnamomea composition, and pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811353402.4A CN109820879A (zh) | 2018-11-14 | 2018-11-14 | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 |
CN201811353402.4 | 2018-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020098329A1 true WO2020098329A1 (zh) | 2020-05-22 |
Family
ID=66859736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/102475 WO2020098329A1 (zh) | 2018-11-14 | 2019-08-26 | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220000952A1 (zh) |
JP (1) | JP2022513042A (zh) |
CN (1) | CN109820879A (zh) |
GB (1) | GB2593380A (zh) |
SG (1) | SG11202104971PA (zh) |
TW (1) | TWI811478B (zh) |
WO (1) | WO2020098329A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109820879A (zh) * | 2018-11-14 | 2019-05-31 | 永腾生技有限公司 | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027362A (zh) * | 2013-03-06 | 2014-09-10 | 财团法人生物技术开发中心 | 用于治疗肺癌的牛樟芝萃取物及其制备方法 |
CN104306410A (zh) * | 2014-09-29 | 2015-01-28 | 深圳市仁泰生物科技有限公司 | 一种富含三萜的抗肿瘤组合物及其制备方法 |
CN104448026A (zh) * | 2014-12-31 | 2015-03-25 | 三生源生物科技(天津)有限公司 | 一种提高牛樟芝多糖抗氧化活性的方法 |
CN109820879A (zh) * | 2018-11-14 | 2019-05-31 | 永腾生技有限公司 | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011162462A (ja) * | 2010-02-08 | 2011-08-25 | National Chung Hsing Univ | ベニクスノキタケ子実体の抽出物およびその用途、antrocamphinAの用途、および炎症誘発性分子生成の抑制方法 |
CN104364467A (zh) * | 2012-01-23 | 2015-02-18 | 越洋塞科外汇合营有限公司 | 用于海洋钻井的高分辨率钻井钻进速度 |
CN104480260B (zh) * | 2014-12-25 | 2016-06-08 | 湖北新冶钢汽车零部件有限公司 | 一种等温正火炉料盘 |
TWI601535B (zh) * | 2016-06-23 | 2017-10-11 | 台灣利得生物科技股份有限公司 | 牛樟段木栽培牛樟芝子實體及固態培養菌絲體水及乙醇萃取物之組合物應用於抗癌藥輔助劑 |
-
2018
- 2018-11-14 CN CN201811353402.4A patent/CN109820879A/zh active Pending
-
2019
- 2019-08-26 SG SG11202104971PA patent/SG11202104971PA/en unknown
- 2019-08-26 JP JP2021526451A patent/JP2022513042A/ja active Pending
- 2019-08-26 GB GB2107582.5A patent/GB2593380A/en not_active Withdrawn
- 2019-08-26 WO PCT/CN2019/102475 patent/WO2020098329A1/zh active Application Filing
- 2019-08-26 US US17/292,610 patent/US20220000952A1/en active Pending
- 2019-11-05 TW TW108140127A patent/TWI811478B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027362A (zh) * | 2013-03-06 | 2014-09-10 | 财团法人生物技术开发中心 | 用于治疗肺癌的牛樟芝萃取物及其制备方法 |
CN104306410A (zh) * | 2014-09-29 | 2015-01-28 | 深圳市仁泰生物科技有限公司 | 一种富含三萜的抗肿瘤组合物及其制备方法 |
CN104448026A (zh) * | 2014-12-31 | 2015-03-25 | 三生源生物科技(天津)有限公司 | 一种提高牛樟芝多糖抗氧化活性的方法 |
CN109820879A (zh) * | 2018-11-14 | 2019-05-31 | 永腾生技有限公司 | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 |
Also Published As
Publication number | Publication date |
---|---|
SG11202104971PA (en) | 2021-06-29 |
GB202107582D0 (en) | 2021-07-14 |
JP2022513042A (ja) | 2022-02-07 |
CN109820879A (zh) | 2019-05-31 |
GB2593380A (en) | 2021-09-22 |
TW202017578A (zh) | 2020-05-16 |
US20220000952A1 (en) | 2022-01-06 |
TWI811478B (zh) | 2023-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
JP6209579B2 (ja) | 補助化療薬品とされる医薬組成物その用途 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
WO2018166151A1 (zh) | 一种用于治疗肿瘤的中药组合物及其制备方法和用途 | |
WO2020098329A1 (zh) | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 | |
JP6893364B2 (ja) | 牛樟芝抗がん活性組成物の製造方法 | |
CN112891362B (zh) | 一种用于治疗脓毒症的药物组合物及其应用 | |
CN111588714B (zh) | 一种用于治疗肺癌的药物组合物及其制备方法 | |
CN109172549B (zh) | 一种抗肿瘤活性组合物及其应用 | |
Toshkova et al. | Influence of purified saponin mixture from Astragalus corniculatus Bieb. on phagocytic cells in Graffi-tumor bearing hamsters | |
CN102335180B (zh) | 乌苏烷类化合物在制备抗肿瘤药物中的应用 | |
CN107929344B (zh) | 一种用于预防及治疗喉癌的紫草复方组合物 | |
CN115212247B (zh) | 一种白刺花花制备物及其应用 | |
CN109867657B (zh) | 二羟二苯并[b,f][1,5]二氧杂辛环类化合物、制备方法及其药用组合物和应用 | |
CN115737691B (zh) | 一种灵芝强效应组分及其制备方法 | |
TWI462742B (zh) | 中草藥萃取物用以製備抑制肉瘤細胞生長之藥物的用途 | |
CN113875494A (zh) | 一种可抗癌细胞增殖及调节肿瘤免疫的功能香菇的培养方法 | |
CN100553662C (zh) | 一种抗肿瘤的中药组合物及其制备方法 | |
CN110693878A (zh) | 石斛酮碱用于制备抗多发性骨髓瘤的药物的用途 | |
CN116549499A (zh) | 商陆果发酵液提取物有效部位在制备抗肿瘤药物中的用途 | |
CN112641820A (zh) | 一种含有nmn的改善更年期症状的药物组合物 | |
CN113101337A (zh) | 一种减缓乳腺癌细胞分裂的药物及其制备方法 | |
CN109010569A (zh) | 一种具有抗肺癌作用的药物组合物及其制备方法 | |
WO2017086892A1 (en) | An extract for cancer treatment | |
CN101164552A (zh) | 蜈蚣多糖蛋白抗肿瘤胶囊剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19883940 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021526451 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 202107582 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20190826 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19883940 Country of ref document: EP Kind code of ref document: A1 |